1,211
Participants
Start Date
June 30, 2008
Primary Completion Date
July 26, 2013
Study Completion Date
November 26, 2018
ipilimumab
IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
Placebo
IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
Local Institution, Westmead
Local Institution, Waratah
Local Institution, Leuven
Local Institution, Box Hill
Local Institution, Malvern
Local Institution, Woolloongabba
Local Institution, Greenslopes
Local Institution, Odense C
Local Institution, Nedlands
Local Institution, Aarhus C
Local Institution, Zurich
Local Institution, Ghent
Memorial Sloan Kettering Cancer Center, New York
Local Institution, Berlin
Local Institution, Prague
Local Institution, Marseille
Local Institution, Genova
St Lukes Hospital And Health Network, Bethlehem
Local Institution, Milan
Local Institution, Turku
Local Institution, Lübeck
Local Institution, Kiel
Local Institution, Madrid
Levine Cancer Institute, Charlotte
Boca Raton Comprehensive Cancer Center, Boca Raton
H Lee Moffitt Cancer Cnt And Res Inst, Tampa
Local Institution, Padua
Local Institution, Göttingen
Vanderbilt-Ingram Cancer Ctr, Nashville
Local Institution, Essen
Local Institution, Zaragoza
Local Institution, Cologne
Local Institution, Siena
Local Institution, Vandœuvre-lès-Nancy
Local Institution, Lillie
Oncology Specialists, S.C., Park Ridge
Washington University School Of Medicine, St Louis
Local Institution, Mannheim
Local Institution, Heidelberg
Local Institution, Pierre-Bénite
Local Institution, Tübingen
Local Institution, Paris
Local Institution, Paris
Center For Oncology Research & Treatment, P.A., Dallas
Local Institution, Napoli
Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City
University Of New Mexico Cancer Center, Albuquerque
Nevada Cancer Center, Las Vegas
The Angeles Clinic & Research Institute, Los Angeles
Local Institution, Boulogne-Billancourt
Sharp Memorial Hospital, San Diego
California Pacific Medical Center, San Francisco
North. Cal. Melanoma Center-St. Mary's Medical Center, San Francisco
Local Institution, Villejuif
Local Institution, Würzburg
Seattle Cancer Care Alliance, Seattle
Local Institution, Moscow
Local Institution, Ivanovo
Local Institution, Petrozavodsk
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Krasnodar
Local Institution, Pyatigorsk
Local Institution, Lipetsk
Local Institution, Saratov
Local Institution, Izhevsk
Local Institution, Ufa
Local Institution, Tomsk
Local Institution, Krasnoyarsk
Yale University School Of Medicine, New Haven
Dana Farber Cancer Institute, Boston
Atlantic Melanoma Center, Morristown
Local Institution, Graz
Local Institution, Vienna
Local Institution, Calgary
Local Institution, Edmonton
Local Institution, Montreal
Local Institution, Prague
Local Institution, Herlev
Local Institution, Helsinki
Local Institution, Roma
Local Institution, Amsterdam
Local Institution, Amsterdam
Local Institution, Leiden
Local Institution, Nijmegen
Local Institution, Rotterdam
Local Institution, Oslo
Local Institution, Poznan
Local Institution, Warsaw
Local Institution, Barcelona
Local Institution, Stockholm
Local Institution, Chelmsford
Local Institution, London
Local Institution, Southampton
Local Institution, Nottingham
Local Institution, Leeds
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY